MedTrace Logo

Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors

NCT01188499 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2016-05-30

Study results available
· View outcomes & findings →

Summary

This is a dose escalation safety study of birinapant (TL32711) in combination with chemotherapy in subjects with advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

Birinapant

Sponsors & Collaborators

  • TetraLogic Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • John N Nemunaitis, MD · Mary Crowley Cancer Research Center

  • Ravi Amaravadi, MD · University of Pennsylvania, Abramson Cancer Center

  • Lainie P Martin, MD · Fox Chase Cancer Center

  • Alex Adjei, MD, PhD · Roswell Park Cancer Institute

  • Patricia LoRusso, DO · Barbara Ann Karmanos Cancer Center

  • Kyriakos P Papadopoulos, MD · South Texas Accelerated Research Therapeutics (START)

  • Zdenka Segota, MD · Holy Cross Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-10-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01188499 on ClinicalTrials.gov